Study of Pathophysiology of Status Epilepticus and Dysimmune Encephalitis
Paraules clau
Resum
Descripció
Epilepsy is one of the most common neurological condition which concerns around 50 million people worldwide. Epilepsy is characterized by a lasting predisposition to generate seizures. Epilepsy can present as heterogenous set of clinical symptoms and is related to extremely varied etiologies. Some epilepsies are triggered by antineuronal autoantibodies and/or complicated by a status epilepticus. These conditions may induce brain atrophy, and severe neurological sequels.
The severity of these epilepsies requires significant efforts to (i) identify new therapeutic strategies able to control the evolution of dysimmune encephalitis and refractory status epilepticus, (ii) to identify their etiologies and (iii) to propose neuroprotective strategies.
Therefore, the investigators will organize a collection of biological samples (blood, cerebrospinal fluid, post-mortem brain tissues) and paraclinical data (electroencephalogram, evoked potential, CT, MRI) in patients with severe epilepsies, whether or not associated with autoantibodies, and/or evolving into status epilepticus.
This study should bring new insights allowing to better understand mechanisms that trigger the emergence of an epileptic brain (epileptogenesis) through :
(i) the identification and characterization of new pathophysiological pathways involving autoimmunity directed against the cerebral cortex and associated with severe epilepsy (ii) the identification and characterization of pathophysiological pathways participating in the excitotoxicity observed in status epilepticus.
Dates
| Darrera verificació: | 04/30/2020 |
| Primer enviat: | 06/03/2020 |
| Inscripció estimada enviada: | 06/03/2020 |
| Publicat per primera vegada: | 06/08/2020 |
| Última actualització enviada: | 06/10/2020 |
| Publicació de l'última actualització: | 06/15/2020 |
| Data d'inici de l'estudi real: | 08/31/2020 |
| Data estimada de finalització primària: | 05/31/2027 |
| Data estimada de finalització de l’estudi: | 05/31/2027 |
Condició o malaltia
Intervenció / tractament
Other: Blood sampling, cerebrospinal fluid , post-mortem cerebral tissues (NA for the Group 3)
Fase
Grups de braços
| Braç | Intervenció / tractament |
|---|---|
| Other: Group 1 : Status epilepticus | |
| Other: Group 2 : Dysimmune encephalitis | |
| Other: Group 3 : Control patients |
Criteris d'elegibilitat
| Edats elegibles per estudiar | 18 Years Per a 18 Years |
| Sexes elegibles per estudiar | All |
| Accepta voluntaris saludables | Sí |
| Criteris | Inclusion Criteria: Group 1: - Patients aged 18 years or above, with status epilepticus. - Affiliation to a French social security system excluding "Aide Médicale" Etat (AME). - Patients or relatives have been informed and given free informed and written consent to participate. Group 2: - Patients aged 18 years or above, with clinical signs of epilepsy associated to dysimmune encephalitis. - Affiliation to a French social security system excluding "Aide Médicale" Etat (AME). - Patients or relatives have been informed and given free informed and written consent to participate. Group 3: - Patients aged 18 years or above, without status epilepticus and/or dysimmune encephalitis. - Affiliation to a French social security system excluding "Aide Médicale" Etat (AME). - Patients or relatives have been informed and given free informed and written consent to participate. Exclusion Criteria: Group 1: - Women with known or clinically detected pregnancy. - Protected adults. - Patients with known neurodegenerative disease. Group 2: - Women with known or clinically detected pregnancy. - Protected adults. - Patients have been already treated by corticoids or IgIV. Group 3: - Women with known or clinically detected pregnancy. - Protected adults. - Patients with status epilepticus. - Patients with known neurodegenerative disease, brain tumor, severe head trauma, meningitis, subarachnoid hemorrhages, stroke. |
Resultat
Mesures de resultats primaris
1. Identification of (i) antibodies in the plasma and in the cerebrospinal fluid of patients with dysimmune encephalitis and (ii) biomarkers for neuronal death in the plasma and in the cerebrospinal fluid of patients with status epilepticus [9 months]
Mesures de resultats secundaris
1. Identification of new dysimmune abnormalities [9 months]
2. Identification of specific EEG patterns associated to dysimmune encephalitis and/or status epilepticus [9 months]
3. Identification of new genetic pathways associated to dysimmune encephalitis and status [9 months]
4. Identification of new metabolic pathway that may participate in the excitotoxicity observed in status epilepticus or dysimmune encephalitis [9 months]
